Dianthus Therapeutics, Inc. /DE/ Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent of -4.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch · last filed 2026-03-09
- Dianthus Therapeutics, Inc. /DE/ effective income tax rate reconciliation, tax credit, research, percent for fiscal 2025 was -4.50%.
- Dianthus Therapeutics, Inc. /DE/ effective income tax rate reconciliation, tax credit, research, percent for fiscal 2024 was -7.50%.
- Dianthus Therapeutics, Inc. /DE/ effective income tax rate reconciliation, tax credit, research, percent for fiscal 2023 was -34.50%, a 1668.18% decline from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ effective income tax rate reconciliation, tax credit, research, percent for fiscal 2022 was 2.20%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -4.50% 10-K · filed 2026-03-09 | |
| 2024-12-31 | -7.50% 10-K · filed 2026-03-09 | |
| 2023-12-31 | -34.50% 10-K · filed 2025-03-11 | 34.50% 10-K · filed 2024-03-21 |
| 2022-12-31 | 2.20% 10-K · filed 2024-03-21 | 4.10% 10-K · filed 2023-03-23 |
| 2021-12-31 | 2.50% 8-K · filed 2023-12-21 | -3.30% 10-K · filed 2022-03-08 |
| 2020-12-31 | -3.40% 10-K · filed 2022-03-08 | |
| 2019-12-31 | -4.10% 10-K · filed 2021-03-03 | |
| 2018-12-31 | -4.70% 10-K · filed 2020-03-03 | |
| 2017-12-31 | -3.40% 10-K · filed 2020-03-03 | |
| 2016-12-31 | -1.80% 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |